ArticleThrombosis research2013
Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT.
Article in Thrombosis research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.European heart journal open · 2026Article
- Cellular and enzymatic features of thrombi in humans are vascular bed dependent.Blood vessels, thrombosis & hemostasis · 2025Article
- Trauma diagnostic-related target proteins and their detection techniques.Expert reviews in molecular medicine · 2024Review
- Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling.Annals of biomedical engineering · 2024Review
- Current challenges in the prevention and management of post-thrombotic syndrome-towards improved prevention.International journal of hematology · 2023Review
- Sustained and intermittent hypoxia differentially modulate primary monocyte immunothrombotic responses to IL-1β stimulation.Frontiers in immunology · 2023Article
- Expression and role of interleukin-1β and associated biomarkers in deep vein thrombosis.Experimental and therapeutic medicine · 2021Article
- Continuing to Advance the Venous Agenda: Long-Term Insights From the CAVA Trial.Journal of the American Heart Association · 2021Article
- Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects.Circulation · 2021Article
- Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2021Article
- Insights from experimental post-thrombotic syndrome and potential for novel therapies.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Reactive Oxygen Species in Venous Thrombosis.International journal of molecular sciences · 2020Review
- Depletion of CD4 and CD8 Positive T Cells Impairs Venous Thrombus Resolution in Mice.International journal of molecular sciences · 2020Article
- Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome.PloS one · 2020Article
- Fibrinolysis and Inflammation in Venous Thrombus Resolution.Frontiers in immunology · 2019Review
- Pre-Clinical Model to Study Recurrent Venous Thrombosis in the Inferior Vena Cava.Thrombosis and haemostasis · 2018Article
- MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α.Journal of thrombosis and thrombolysis · 2018Article
- Divergent effects of Tlr9 deletion in experimental late venous thrombosis resolution and vein wall injury.Thrombosis and haemostasis · 2015Article
- Matrix Metalloproteinase 9 (MMP-9) Regulates Vein Wall Biomechanics in Murine Thrombus Resolution.PloS one · 2015Article
- Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.Journal of thrombosis and haemostasis : JTH · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
introductionPost thrombotic syndrome therapy is primarily palliative, and the associated vein wall inflammatory mechanisms are unclear. Vein wall fibrotic injury following deep venous thrombosis (VT) is associated with elevated matrix metalloproteinases (MMPs). Whether and by what mechanism MMP9 directly contributes to vein wall remodeling after VT is unknown.
methodsWT and MMP9 -/- mice underwent stasis VT by ligation of the inferior vena cava (IVC) and tissue was harvested at 2, 8, and 21days. Assessment of thrombus size, and gene, protein and structural vein wall determinations were done.
resultsVT resolution was increased in MMP9-/- mice as compared with controls at 21d only. The primary phenotypic fibrotic vein wall differences occurred at 8d post VT, with significantly less vein wall collagen content as assessed by Picosirius red staining in MMP9 -/- mice as compared with WT. Increased monocytic vein wall influx with less IL-1b and TGFb was found in MMP9 -/- vein walls as compared with WT. Corresponding levels of PAI-1 were increased in MMP9 -/- compared with WT, and no difference in FSP-1+cells as compared with controls.
conclusionsIn stasis VT, MMP9 modulates midterm vein wall collagen content, with an altered local inflammatory and profibrotic environment, likely directed by monocytes. Thus, MMP9 plays a role in both vein wall responses as well as late thrombus resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.